BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Trivedi PJ, Adams DH. Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise. J Crohns Colitis. 2018;12:S641-S652. [PMID: 30137309 DOI: 10.1093/ecco-jcc/jjx145] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Couvineau A, Voisin T, Nicole P, Gratio V, Blais A. Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions. World J Gastroenterol 2021; 27(44): 7582-7596 [PMID: 34908800 DOI: 10.3748/wjg.v27.i44.7582] [Reference Citation Analysis]
2 Xu X, Zhang L, Zhao Y, Xu B, Qin W, Yan Y, Yin B, Xi C, Ma L. Anti‑inflammatory mechanism of berberine on lipopolysaccharide‑induced IEC‑18 models based on comparative transcriptomics. Mol Med Rep 2020;22:5163-80. [PMID: 33174609 DOI: 10.3892/mmr.2020.11602] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Murray EJ, Gumusoglu SB, Santillan DA, Santillan MK. Manipulating CD4+ T Cell Pathways to Prevent Preeclampsia. Front Bioeng Biotechnol 2022;9:811417. [DOI: 10.3389/fbioe.2021.811417] [Reference Citation Analysis]
4 Rein D, Ternes P, Demin R, Gierke J, Helgason T, Schön C. Artificial intelligence identified peptides modulate inflammation in healthy adults. Food Funct 2019;10:6030-41. [PMID: 31483433 DOI: 10.1039/c9fo01398a] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
5 Keely SJ, Steer CJ, Lajczak-McGinley NK. Ursodeoxycholic acid: a promising therapeutic target for inflammatory bowel diseases? Am J Physiol Gastrointest Liver Physiol 2019;317:G872-81. [PMID: 31509435 DOI: 10.1152/ajpgi.00163.2019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
6 Tong X, Zheng Y, Li Y, Xiong Y, Chen D. Soluble ligands as drug targets for treatment of inflammatory bowel disease. Pharmacol Ther 2021;226:107859. [PMID: 33895184 DOI: 10.1016/j.pharmthera.2021.107859] [Reference Citation Analysis]
7 Ju JK, Cho YN, Park KJ, Kwak HD, Jin HM, Park SY, Kim HS, Kee SJ, Park YW. Activation, Deficiency, and Reduced IFN-γ Production of Mucosal-Associated Invariant T Cells in Patients with Inflammatory Bowel Disease. J Innate Immun 2020;12:422-34. [PMID: 32535589 DOI: 10.1159/000507931] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Giannoudaki E, Gargan S, Hussey S, Long A, Walsh PT. Opportunities to Target T Cell Trafficking in Pediatric Inflammatory Bowel Disease. Front Pediatr 2021;9:640497. [PMID: 33816403 DOI: 10.3389/fped.2021.640497] [Reference Citation Analysis]
9 Sjöbom U, Christenson K, Hellström A, Nilsson AK. Inflammatory Markers in Suction Blister Fluid: A Comparative Study Between Interstitial Fluid and Plasma. Front Immunol 2020;11:597632. [PMID: 33224151 DOI: 10.3389/fimmu.2020.597632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Myles EM, O'Leary ME, Smith R, MacPherson CW, Oprea A, Melanson EH, Tompkins TA, Perrot TS. Supplementation with Combined Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 Across Development Reveals Sex Differences in Physiological and Behavioural Effects of Western Diet in Long-Evans Rats. Microorganisms 2020;8:E1527. [PMID: 33027912 DOI: 10.3390/microorganisms8101527] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Portillo JC, Yu JS, Hansen S, Kern TS, Subauste MC, Subauste CS. A cell-penetrating CD40-TRAF2,3 blocking peptide diminishes inflammation and neuronal loss after ischemia/reperfusion. FASEB J 2021;35:e21412. [PMID: 33675257 DOI: 10.1096/fj.201903203RR] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Misselwitz B, Wyss A, Raselli T, Cerovic V, Sailer AW, Krupka N, Ruiz F, Pot C, Pabst O. The oxysterol receptor GPR183 in inflammatory bowel diseases. Br J Pharmacol 2021;178:3140-56. [PMID: 33145756 DOI: 10.1111/bph.15311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Wiendl M, Becker E, Müller TM, Voskens CJ, Neurath MF, Zundler S. Targeting Immune Cell Trafficking - Insights From Research Models and Implications for Future IBD Therapy. Front Immunol 2021;12:656452. [PMID: 34017333 DOI: 10.3389/fimmu.2021.656452] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Skovdahl HK, Gopalakrishnan S, Svendsen TD, Granlund AVB, Bakke I, Ginbot ZG, Thorsvik S, Flatberg A, Sporsheim B, Ostrop J, Mollnes TE, Sandvik AK, Bruland T. Patient Derived Colonoids as Drug Testing Platforms-Critical Importance of Oxygen Concentration. Front Pharmacol 2021;12:679741. [PMID: 34054553 DOI: 10.3389/fphar.2021.679741] [Reference Citation Analysis]
15 Liu F, Wu H. CC Chemokine Receptors in Lung Adenocarcinoma: The Inflammation-Related Prognostic Biomarkers and Immunotherapeutic Targets. J Inflamm Res 2021;14:267-85. [PMID: 33574689 DOI: 10.2147/JIR.S278395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Camba-Gómez M, Arosa L, Gualillo O, Conde-Aranda J. Chemokines and chemokine receptors in inflammatory bowel disease: Recent findings and future perspectives. Drug Discov Today 2021:S1359-6446(21)00538-9. [PMID: 34896626 DOI: 10.1016/j.drudis.2021.12.004] [Reference Citation Analysis]
17 Dharmasiri S, Garrido-Martin EM, Harris RJ, Bateman AC, Collins JE, Cummings JRF, Sanchez-Elsner T. Human Intestinal Macrophages Are Involved in the Pathology of Both Ulcerative Colitis and Crohn Disease. Inflamm Bowel Dis 2021:izab029. [PMID: 33570153 DOI: 10.1093/ibd/izab029] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Moisset X, Giraud P, Dallel R. Migraine in multiple sclerosis and other chronic inflammatory diseases. Rev Neurol (Paris) 2021:S0035-3787(21)00616-0. [PMID: 34325914 DOI: 10.1016/j.neurol.2021.07.005] [Reference Citation Analysis]
19 Matsuoka K, Naganuma M, Hibi T, Tsubouchi H, Oketani K, Katsurabara T, Hojo S, Takenaka O, Kawano T, Imai T, Kanai T. Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn's disease. J Gastroenterol Hepatol 2021;36:2180-6. [PMID: 33599356 DOI: 10.1111/jgh.15463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Yang Y, Li L, Xu C, Wang Y, Wang Z, Chen M, Jiang Z, Pan J, Yang C, Li X, Song K, Yan J, Xie W, Wu X, Chen Z, Yuan Y, Zheng S, Yan J, Huang J, Qiu F. Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis. Gut 2020:gutjnl-2020-320777. [PMID: 33122176 DOI: 10.1136/gutjnl-2020-320777] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
21 Adams DH. More Levels of Complexity in the Control of Intestinal Inflammation. Cell Mol Gastroenterol Hepatol 2021;12:791-2. [PMID: 34181900 DOI: 10.1016/j.jcmgh.2021.06.009] [Reference Citation Analysis]
22 Ikawa T, Miyagawa T, Fukui Y, Toyama S, Omatsu J, Awaji K, Norimatsu Y, Watanabe Y, Yoshizaki A, Sato S, Asano Y. Endothelial CCR6 expression due to FLI1 deficiency contributes to vasculopathy associated with systemic sclerosis. Arthritis Res Ther 2021;23:283. [PMID: 34774095 DOI: 10.1186/s13075-021-02667-9] [Reference Citation Analysis]
23 Qin C, Liu H, Tang B, Cao M, Yu Z, Liu B, Liu W, Dong Y, Ren H. In Vitro Immunological Effects of CXCR3 Inhibitor AMG487 on Dendritic Cells. Arch Immunol Ther Exp (Warsz) 2020;68:11. [PMID: 32239302 DOI: 10.1007/s00005-020-00577-3] [Reference Citation Analysis]
24 Meitei HT, Jadhav N, Lal G. CCR6-CCL20 axis as a therapeutic target for autoimmune diseases. Autoimmun Rev 2021;20:102846. [PMID: 33971346 DOI: 10.1016/j.autrev.2021.102846] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 El-saka AM, Zamzam YA, Haydara T, Abd-elsalam S. Immunohistochemical staining with chemokine panel of non-specific colitis predicts future IBD diagnosis. Cytokine 2020;127:154935. [DOI: 10.1016/j.cyto.2019.154935] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Augustino SMA, Xu Q, Liu X, Liu L, Zhang Q, Yu Y. Transcriptomic Study of Porcine Small Intestine Epithelial Cells Reveals Important Genes and Pathways Associated With Susceptibility to Escherichia coli F4ac Diarrhea. Front Genet 2020;11:68. [PMID: 32174961 DOI: 10.3389/fgene.2020.00068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Zhao B, Yin Q, Fei Y, Zhu J, Qiu Y, Fang W, Li Y. Research progress of mechanisms for tight junction damage on blood-brain barrier inflammation. Arch Physiol Biochem 2020;:1-12. [PMID: 32608276 DOI: 10.1080/13813455.2020.1784952] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
28 Miao M, De Clercq E, Li G. Clinical significance of chemokine receptor antagonists. Expert Opin Drug Metab Toxicol 2020;16:11-30. [PMID: 31903790 DOI: 10.1080/17425255.2020.1711884] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 15.5] [Reference Citation Analysis]
29 Shi L, Han X, Li JX, Liao YT, Kou FS, Wang ZB, Shi R, Zhao XJ, Sun ZM, Hao Y. Identification of differentially expressed genes in ulcerative colitis and verification in a colitis mouse model by bioinformatics analyses. World J Gastroenterol 2020; 26(39): 5983-5996 [PMID: 33132649 DOI: 10.3748/wjg.v26.i39.5983] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
30 Stürzl M, Kunz M, Krug SM, Naschberger E. Angiocrine Regulation of Epithelial Barrier Integrity in Inflammatory Bowel Disease. Front Med (Lausanne) 2021;8:643607. [PMID: 34409045 DOI: 10.3389/fmed.2021.643607] [Reference Citation Analysis]
31 Volarevic V, Zdravkovic N, Harrell CR, Arsenijevic N, Fellabaum C, Djonov V, Lukic ML, Simovic Markovic B. Galectin-3 Regulates Indoleamine-2,3-dioxygenase-Dependent Cross-Talk between Colon-Infiltrating Dendritic Cells and T Regulatory Cells and May Represent a Valuable Biomarker for Monitoring the Progression of Ulcerative Colitis. Cells 2019;8:E709. [PMID: 31336879 DOI: 10.3390/cells8070709] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
32 Fiedler D, Hartl S, Gerlza T, Trojacher C, Kungl A, Khinast J, Roblegg E. Comparing freeze drying and spray drying of interleukins using model protein CXCL8 and its variants. Eur J Pharm Biopharm 2021;168:152-65. [PMID: 34474111 DOI: 10.1016/j.ejpb.2021.08.006] [Reference Citation Analysis]
33 Kong C, Yan X, Liu Y, Huang L, Zhu Y, He J, Gao R, Kalady MF, Goel A, Qin H, Ma Y. Ketogenic diet alleviates colitis by reduction of colonic group 3 innate lymphoid cells through altering gut microbiome. Signal Transduct Target Ther 2021;6:154. [PMID: 33888680 DOI: 10.1038/s41392-021-00549-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Xu J, Neal LM, Ganguly A, Kolbe JL, Hargarten JC, Elsegeiny W, Hollingsworth C, He X, Ivey M, Lopez R, Zhao J, Segal B, Williamson PR, Olszewski MA. Chemokine receptor CXCR3 is required for lethal brain pathology but not pathogen clearance during cryptococcal meningoencephalitis. Sci Adv 2020;6:eaba2502. [PMID: 32596454 DOI: 10.1126/sciadv.aba2502] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
35 Peng K, Xiao J, Wang J, Song Y, Wu L, Xiu W, Chen Q, Chen Y, Shuai P, He C, Lu F. MAdCAM-1 mediates retinal neuron degeneration in experimental colitis through recruiting gut-homing CD4+ T cells. Mucosal Immunol 2021;14:152-63. [PMID: 32203063 DOI: 10.1038/s41385-020-0282-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Sato N, Garcia-Castillo V, Yuzawa M, Islam MA, Albarracin L, Tomokiyo M, Ikeda-Ohtsubo W, Garcia-Cancino A, Takahashi H, Villena J, Kitazawa H. Immunobiotic Lactobacillus jensenii TL2937 Alleviates Dextran Sodium Sulfate-Induced Colitis by Differentially Modulating the Transcriptomic Response of Intestinal Epithelial Cells. Front Immunol. 2020;11:2174. [PMID: 33042131 DOI: 10.3389/fimmu.2020.02174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Xiao Q, Li X, Li Y, Wu Z, Xu C, Chen Z, He W. Biological drug and drug delivery-mediated immunotherapy. Acta Pharm Sin B 2021;11:941-60. [PMID: 33996408 DOI: 10.1016/j.apsb.2020.12.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]